Jermutus, Lutz

LEAP2 Is an Endogenous Antagonist of the Ghrelin Receptor

Ge, X., Yang, H., Bednarek, M. A., Galon-Tilleman, H., Chen, P., Chen, M., Lichtman, J. S., Wang, Y., Dalmas, O., Yin, Y., et al. (2018) · Cell Metabolism

Regulation of Appetite and ObesityNeuropeptides and Animal Physiology

Cited by 376

Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study

Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care

Diabetes Treatment and ManagementLiver Disease Diagnosis and Treatment

Cited by 323

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study

Ambery, P., Parker, V. E., Stumvoll, M., Posch, M. G., Heise, T., Plum-Moerschel, L., Tsai, L.-F., Robertson, D., Jain, M., Petrone, M., et al. (2018) · The Lancet

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 298

Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis

Boland, M. L., Laker, R. C., Mather, K., Nawrocki, A., Oldham, S., Boland, B. B., Lewis, H., Conway, J., Naylor, J., Guionaud, S., et al. (2020) · Nature Metabolism

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 270

Robust anti‐obesity and metabolic effects of a dual GLP ‐1/glucagon receptor peptide agonist in rodents and non‐human primates

Henderson, S. J., Konkar, A., Hornigold, D. C., Trevaskis, J. L., Jackson, R., Fritsch Fredin, M., Jansson‐Löfmark, R., Naylor, J., Rossi, A., Bednarek, M. A., et al. (2016) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 240

Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease

Parker, V. E. R., Hoang, T., Schlichthaar, H., Gibb, F. W., Wenzel, B., Posch, M. G., Rose, L., Chang, Y., Petrone, M., Hansen, L., et al. (2022) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 80

MEDI0382, a GLP‐1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single‐dose, healthy‐subject, randomized, Phase 1 study

Ambery, P. D., Klammt, S., Posch, M. G., Petrone, M., Pu, W., Rondinone, C., Jermutus, L., & Hirshberg, B. (2018) · British Journal of Clinical Pharmacology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 75

Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes

Parker, V. E. R., Robertson, D., Erazo-Tapia, E., Havekes, B., Phielix, E., de Ligt, M., Roumans, K. H. M., Mevenkamp, J., Sjoberg, F., Schrauwen-Hinderling, V. B., et al. (2023) · Nature Metabolism

Diabetes Treatment and ManagementLiver Disease Diagnosis and Treatment

Cited by 53

A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease

Selvarajah, V., Robertson, D., Hansen, L., Jermutus, L., Smith, K., Coggi, A., Sánchez, J., Chang, Y.-T., Yu, H., Parkinson, J., et al. (2024) · Kidney International

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 49

A novel long-acting relaxin-2 fusion, AZD3427, improves cardiac performance in non-human primates with cardiac dysfunction

Papworth, M., Kulkarni, S., Antonsson, M., Sermadiras, I., Hovdal, D., Connolly, K., Olsson, J., Shukla, A., Cotton, P., Althage, M., et al. (2025) · Cardiovascular Research

Pregnancy-related medical researchCardiac Fibrosis and Remodeling

Cited by 8